HDAC6 is involved in tau aggregation and phosphorylation in neurons and human AD brain61,62, and Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC activity to be studied clinically for treatment of multiple myeloma63. The gene discussed is MAPT; the disease is Alzheimer disease.